Core Viewpoint - Xianfeng Holdings (stock code: 002141) has approved the proposal to terminate relevant agreements related to its subsidiary Kangxiyuan's feed business, indicating a strategic exit from this sector [1] Group 1: Agreement Termination - The board of Xianfeng Holdings convened on September 26, 2025, to review and approve the termination of agreements with Zunyi Riquan and other companies regarding the leasing and purchasing of feed factories [1] - Kangxiyuan plans to negotiate the termination of these agreements and exit the feed business, with the handover process to be completed gradually after the agreements are signed [1] Group 2: Financial Implications - The agreement regarding the termination of the feed purchase and sales agreements stipulates that all outstanding payments must be settled by October 15, 2025 [1] - The rental contract termination agreement specifies that the landlord must return 488,200 yuan in rent by October 15 [1] - The termination of these agreements is not expected to have a significant impact on the company's future operations [1]

Market Overview - On September 25, the animal health sector declined by 1.62% compared to the previous trading day, with the leading stock, Driveline, experiencing a drop of 4.04% [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - The following stocks in the animal health sector showed notable declines: - Driveline (Code: 838275) closed at 9.50, down 4.04% with a trading volume of 19,300 lots [1] - Shunlian Bio (Code: 688098) closed at 10.43, down 3.43% with a trading volume of 76,300 lots [1] - Yongshun Bio (Code: 839729) closed at 9.74, down 2.89% with a trading volume of 20,800 lots [1] - Other notable declines include *ST Green Health (Code: 002868) down 2.39% and Shoufeng Holdings (Code: 002141) down 2.33% [1] Capital Flow - The animal health sector saw a net outflow of 113 million yuan from institutional investors, while retail investors experienced a net inflow of 61.16 million yuan [1] - The following stocks had significant capital flow: - Zhongmu Co. (Code: 600195) had a net inflow of 986,800 yuan from institutional investors [2] - Pulaike (Code: 603566) saw a net inflow of 764,200 yuan from retail investors [2] - *ST Green Health (Code: 002868) experienced a net outflow of 6.71 million yuan from institutional investors [2]

Core Viewpoint - The investor relations event held on September 19, 2025, focused on the core businesses of Xianfeng Holdings, particularly in the fields of copper-clad laminates and animal health vaccines, attracting significant market attention [1][2]. Group 1: Copper-Clad Laminate Business - Investors showed particular interest in the performance of the copper-clad laminate business since July, focusing on aspects such as product gross margin, customer resources, cost control, and product qualification rates [3]. - The company reported a gross margin improvement in the first half of the year through customer structure optimization and product structure upgrades, achieving a production value of approximately 350 million [3]. - There was no clear indication from the company regarding the mass production of the high-speed M8 copper-clad laminate or the status of mid-to-high-end customers [3]. - The company has established a joint venture with Jiangxi Hangyu to integrate their copper-clad laminate businesses, leveraging complementary strengths for high-performance production [3]. Group 2: Animal Health Vaccine and Other Business Situations - The animal health vaccine business is currently operating normally, and the company is actively working on market expansion, internal cost control, and quality improvement to enhance operational performance [4]. - The company is monitoring the potential auction of 114.15 million shares held by the controlling shareholder and will fulfill its information disclosure obligations regarding any changes [4]. - Despite reporting a loss in the net profit excluding non-recurring items, the company aims to improve its operational situation by expanding market reach and enhancing cost efficiency across all business areas [4]. - The main business focus remains on copper-clad laminates, which are part of the new productivity electronic information industry [4].

Group 1: Business Performance - The core business of copper-clad laminates has shown improvement in gross profit margin, customer resources, cost control, and product qualification rate compared to the first half of the year, achieving a profit of over 200,000 in the first half of 2025 [2][3] - The company has implemented customer structure optimization and product structure upgrades, resulting in a certain degree of gross margin improvement in the first half of the year [3] - The company’s copper-clad laminate business generated an output value of approximately 350 million in the first half of 2025 [3] Group 2: Operational Strategies - The company is actively exploring the market and will further enhance cost control and quality improvement to boost operational efficiency [3][4] - The company is currently engaged in a joint venture with Jiangxi Hangyu to produce high-performance copper-clad laminates, leveraging complementary resources [3] - The company plans to maintain focus on its core business of copper-clad laminates and will not abandon its animal vaccine business, which is operating normally [2][3] Group 3: Investor Relations - The company assures that it will fulfill its information disclosure obligations regarding any changes in the shareholding of its controlling shareholder [3] - The company has not engaged in PCB business and is focused on its core operations [4] - The company is committed to improving its operational status through various measures, despite reporting a loss in its interim results [4]

Market Overview - On September 19, the animal health sector declined by 0.26% compared to the previous trading day, with the driving force leading the decline [1] - The Shanghai Composite Index closed at 3820.09, down 0.3%, while the Shenzhen Component Index closed at 13070.86, down 0.04% [1] Stock Performance - Notable stock movements included: - *ST Lvkang (002868): Closed at 27.56, up 4.99% with a trading volume of 38,500 shares and a turnover of 105 million yuan [1] - Kexin Biological (688526): Closed at 18.08, up 0.39% with a trading volume of 22,700 shares and a turnover of 40.94 million yuan [1] - Driving Force (838275): Closed at 10.50, down 4.11% with a trading volume of 21,200 shares and a turnover of 22.63 million yuan [2] Capital Flow - The animal health sector experienced a net outflow of 91.4 million yuan from institutional investors, while retail investors saw a net inflow of 70.15 million yuan [2] - The capital flow for individual stocks showed: - RuiPu Biological (300119): Net inflow of 16.56 million yuan from institutional investors, but a net outflow of 21.57 million yuan from retail investors [3] - *ST Lvkang (002868): Net inflow of 6.13 million yuan from institutional investors, with a net outflow of 4.21 million yuan from retail investors [3]

Market Overview - On September 18, the animal health sector declined by 0.77% compared to the previous trading day, with Huisheng Biological leading the decline [1] - The Shanghai Composite Index closed at 3831.66, down 1.15%, while the Shenzhen Component Index closed at 13075.66, down 1.06% [1] Stock Performance - The following stocks in the animal health sector showed notable performance: - *ST Lvkang (002868): Closed at 26.25, up 5.00% with a trading volume of 3433 lots [1] - Shengbi Biological (600201): Closed at 66.8, down 2.39% with a trading volume of 55.74 million [1] - Ruipu Biological (300119): Closed at 22.06, unchanged with a trading volume of 111.3 million [1] - Other stocks such as Jinhai Biological (002688) and Shunlian Biological (688098) also experienced declines of 1.98% and 2.02% respectively [1][2] Capital Flow - The animal health sector experienced a net outflow of 126 million yuan from institutional investors, while retail investors saw a net inflow of 92.38 million yuan [2] - The following stocks had significant capital flow: - Ruipu Biological: Net inflow of 12.35 million yuan from institutional investors [3] - *ST Lvkang: Net outflow of 3.83 million yuan from institutional investors [3] - Jinhai Biological: Net outflow of 25.51 million yuan from institutional investors [3]

Market Overview - On September 16, the animal health sector declined by 0.41%, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Stock Performance - Key stocks in the animal health sector showed mixed performance, with the following notable movements: - Xianfeng Holdings (002141) increased by 2.27% to close at 4.06 [1] - Haili Biological (603718) rose by 1.27% to 7.17 [1] - *ST Lvkang (002868) fell by 4.34% to 23.81, leading the decline [2] - The trading volume and turnover for selected stocks were significant, with Xianfeng Holdings achieving a turnover of 1.02 billion [1] Capital Flow Analysis - The animal health sector experienced a net outflow of 15.97 million from institutional investors, while retail investors saw a net inflow of 11.29 million [2][3] - Notable capital flows included: - Biological Shares (600201) had a net inflow of 12.28 million from institutional investors [3] - *ST Lvkang (002868) saw a net outflow of 2.89 million from institutional investors [3] - Retail investors contributed positively to several stocks, including a net inflow of 12.59 million into Shenyuan Biological (688098) [3]

为进一步加强与投资者的互动交流，贤丰控股股份有限公司（以下简称"公 司"）将参加由中国证券监督管理委员会广东监管局和广东上市公司协会联合举 办的"向新提质 价值领航——2025 年广东辖区投资者集体接待日暨辖区上市公 司中报业绩说明会"活动，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景•路演天下"网站 （http://rs.p5w.net）参与本次互动交流。本次活动时间为 2025 年 9 月 19 日（星 期五）15:30-17:00。届时公司高管将在线就公司业绩情况、公司治理、发展战略、 经营状况等投资者关心的问题，与广大投资者作集中说明、互动交流，欢迎广大 投资者积极参与！ 证券代码：002141 证券简称：贤丰控股 公告编号：2025-072 贤丰控股股份有限公司 关于参加广东辖区 2025 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特此公告。 贤丰控股股份有限公司 董事会 2025 年 9 月 16 日 ...

Core Insights - The animal health sector experienced a 1.14% increase on September 15, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index closed at 13005.77, up 0.63% [1] Stock Performance - BioShares (600201) closed at 8.82, up 7.17% with a trading volume of 624,100 shares and a turnover of 539 million yuan [1] - Dayu Biological (871970) closed at 11.50, up 6.09% with a trading volume of 124,300 shares and a turnover of 139 million yuan [1] - Other notable performers include: - Jinhai Biological (002688) at 7.20, up 3.00% [1] - Ruipu Biological (300119) at 21.98, up 1.76% [1] - Zhongmu Co. (600195) at 7.50, up 1.63% [1] Capital Flow - The animal health sector saw a net outflow of 25.577 million yuan from institutional investors, while retail investors contributed a net inflow of 6.5625 million yuan [2] - The capital flow for individual stocks indicates: - Jinhai Biological had a net inflow of 32.1651 million yuan from institutional investors [3] - Zhongmu Co. had a net inflow of 6.8986 million yuan from institutional investors [3] - Ruipu Biological experienced a net outflow of 1.1475 million yuan from institutional investors [3]

证券日报网讯 9月12日晚间，贤丰控股发布公告称，董事会近日收到公司证券事务代表温秋萍女士的书 面辞职报告。温秋萍女士因个人原因辞去公司证券事务代表职务。辞职后，温秋萍女士不再担任公司任 何职务。温秋萍女士的辞职报告自送达公司董事会之日起生效。 （文章来源：证券日报） ...